Rare disease-focused Prosensa brings in US investor in new €23 million round
This article was originally published in Scrip
Prosensa, the Dutch firm focused on RNA-modulating therapies for rare diseases, has raised €23 million in new venture capital funding. The round was led by new investor New Enterprise Associates and included existing investors Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.